Inflammatory biomarkers in atherosclerosis: Pentraxin 3 can become a novel marker of plaque vulnerability

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Shindo, Akihiro ^a   Tanemura, Hiroshi ^a   Yata, Kenichiro ^a   Hamada, Kazuhide ^a   Shibata, Masunari ^a   Umeda, Yasuyuki ^a   Asakura, Fumio ^a   Toma, Naoki ^a   Sakaida, Hiroshi ^a   Fujisawa, Takao ^b   Taki, Waro ^a   Tomimoto, Hidekazu ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE NATIONAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PENTRAXIN 3; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; BIOLOGICAL MARKER; SERUM AMYLOID P;

ADIPONECTIN BLOOD LEVEL; ADULT; AGED; ARTICLE; BLOOD SAMPLING; C REACTIVE PROTEIN BLOOD LEVEL; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENT; CAROTID ARTERY STENTING; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE MARKER; DOWN REGULATION; E SELECTIN BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL ARTERY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; INTERLEUKIN 10 BLOOD LEVEL; INTERLEUKIN 1BETA BLOOD LEVEL; INTERLEUKIN 6 BLOOD LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PENTRAXIN 3 BLOOD LEVEL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TUMOR NECROSIS FACTOR ALPHA BLOOD LEVEL; UPREGULATION; VASCULAR CELL ADHESION MOLECULE 1 BLOOD LEVEL; VASCULAR ENDOTHELIUM; CAROTID STENOSIS; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID STENOSIS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; SERUM AMYLOID P-COMPONENT;

EID: 84903288792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100045     Document Type: Article

References (41)

1. Ross R (1999) Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126.
2. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92: 657-671.
3. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850.
4. Libby P (2002) Atherosclerosis: the new view. Sci Am 286: 46-55.
5. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, et al. (1994) Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90: 775-778. (Pubitemid 24242744)
6. Davies MJ (1996) Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 94: 2013-2020.
7. Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-32. (Pubitemid 38786440)
8. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, et al. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506-512. (Pubitemid 29231100)
9. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843. (Pubitemid 30165206)
10. Bonacina F, Baragetti A, Catapano AL, Norata GD (2013) Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. Mediators Inflamm 2013: 725102.
11. Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366. (Pubitemid 40563173)
12. North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991) Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325: 445-453.
13. Yadav JS, Wholey MH, Kuntz RE, Fayard P, Katzen BT, et al. (2004) Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351: 1493-1501.
14. Tanemura H, Maeda M, Ichikawa N, Miura Y, Umeda Y, et al. (2013) Highrisk plaque for carotid artery stenting evaluated with 3-dimensional t1-weighted gradient echo sequence. Stroke 44: 105-110.
15. Stary HC (2000) Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 20: 1177-1178.
16. Crouse JR 3rd (2006) Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art. J Lipid Res 47: 1677-1699.
17. Yuan C, Oikawa M, Miller Z, Hatsukami T (2008) MRI of carotid atherosclerosis. J Nucl Cardiol 15: 266-275. (Pubitemid 351396322)
18. Saam T, Hatsukami TS, Takaya N, Chu B, Underhill H, et al. (2007) The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology 244: 64-77. (Pubitemid 46981959)
19. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, et al. (2002) Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 106: 1368-1373. (Pubitemid 35013040)
20. Shenhar-Tsarfaty S, Ben Assayag E, Bova I, Shopin L, Fried M, et al. (2010) Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack. Int J Stroke 5: 16-20.
21. Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, et al. (2003) C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 108: 166-170. (Pubitemid 36871298)
22. Blann AD, Waite MA (1996) von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis 7: 143-147. (Pubitemid 26256421)
23. Wang JY, Zhou DH, Li J, Zhang M, Deng J, et al. (2006) Association of soluble intercellular adhesion molecule 1 with neurological deterioration of ischemic stroke: The Chongqing Stroke Study. Cerebrovasc Dis 21: 67-73. (Pubitemid 43110313)
24. Abe Y, Sakaguchi M, Furukado S, Fujinaka T, Sakoda S, et al. (2010) Interleukin-6 release after carotid artery stenting and periprocedural new ischemic lesions. J Cereb Blood Flow Metab 30: 857-863.
25. Sakurai S, Kitamura A, Cui R, Yamagishi K, Tanigawa T, et al. (2009) Relationships of soluble E-selectin and high-sensitivity C-reactive protein with carotid atherosclerosis in Japanese men. J Atheroscler Thromb 16: 339-345.
26. Profumo E, Esposito C, Buttari B, Tosti ME, Ortona E, et al. (2007) Intracellular expression of cytokines in peripheral blood from patients with atherosclerosis before and after carotid endarterectomy. Atherosclerosis 191: 340-347. (Pubitemid 46400694)
27. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE (1996) Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 93: 672-682. (Pubitemid 26052452)
28. de Vries JE (1995) Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 27: 537-541.
29. Wozniak SE, Gee LL, Wachtel MS, Frezza EE (2009) Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 54: 1847-1856.
30. Gardener H, Sjoberg C, Crisby M, Goldberg R, Mendez A, et al. (2012) Adiponectin and carotid intima-media thickness in the northern Manhattan study. Stroke 43: 1123-1125.
31. El-Mesallamy HO, Hamdy NM, Salman TM, Mahmoud S (2011) Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s). Minerva Endocrinol 36: 163-170.
32. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, et al. (2004) Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109: 2046-2049. (Pubitemid 38620209)
33. Folco EJ, Rocha VZ, López-Ilasaca M, Libby P (2009) Adiponectin inhibits proinflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem 284: 25569-25575.
34. O'Farrell AM, Liu Y, Moore KW, Mui AL (1998) IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J 17: 1006-1018. (Pubitemid 28077655)
35. Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch J, et al. (2006) C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol 26: 2469-2475. (Pubitemid 44607467)
36. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, et al. (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22: e10-14.
37. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, et al. (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215: 48-55. (Pubitemid 351619875)
38. Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, et al. (2012) Different distribution of pentraxin 3and C-reactive protein in coronary atherosclerotic plaques. J Atheroscler Thromb 19: 837-45.
39. Hermus L, Schuitemaker JH, Tio RA, Breek JC, Slart RH, et al. (2011) Novel serum biomarkers in carotid artery stenosis: useful to identify the vulnerable plaque? Clin Biochem 44: 1292-1298.
40. Ryu WS, Kim CK, Kim BJ, Kim C, Lee SH, at el. (2012) Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 220: 581-586.
41. Norata GD, Garlanda C, Catapano AL (2010) The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20: 35-40.